NEL Animal Cardiovascular Center Achieves World's First Surgical Correction of Complex VSD in Canine Patient
NEL Animal Cardiovascular Center, a private 24-hour animal hospital in South Korea, said that its cardiac surgery team has successfully performed the world's first surgical correction of a complex ventricular septal defect (VSD) in a canine patient.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618427466/en/
NEL Animal Cardiovascular Center's medical staff performing surgical correction of a complex ventricular septal defect (VSD) in a canine patient (Photo: NEL Animal Cardiovascular Center)
This veterinary milestone is highly significant, as it marks the first such case not only in Korea but also globally, with no previous reports of successful surgical treatment for complex VSDs.
The patient was diagnosed with a unique form of VSD—a single, continuous defect extending from the perimembranous to the subarterial region (Perimembranous VSD extending into subarterial region). Given that there had been no prior successful surgical cases even for typical VSDs in veterinary medicine, this breakthrough greatly expands the possibilities for surgical treatment of congenital heart disease in Korea's veterinary cardiac surgery field.
Over the past year, NEL's cardiac surgery team has gained experience through more than 50 open-heart surgeries using cardiopulmonary bypass. Based on this expertise, the team developed a thorough surgical plan. During the procedure, the complex VSD involving both membranous and subarterial regions was confirmed. The team performed incisions in the right atrium and pulmonary artery, successfully closing the defect with a bovine pericardial patch.
Immediately after surgery, the left-to-right shunt was completely resolved, and the risk of progressive regurgitation due to aortic valve prolapse was eliminated. The patient's cardiac function recovered to near-normal levels, and the long-term prognosis is considered highly favorable.
Subarterial VSDs are particularly dangerous due to the risk of aortic valve prolapse and severe regurgitation, making early surgical intervention crucial. The success of this surgery offers new hope for animals with congenital heart defects, demonstrating the potential for a surgical cure.
Dr. Tae-Heum Um, Director of NEL Animal Cardiovascular Center, stated,
'Although this was a complex defect, thorough discussion and preparation among our medical team led to a successful outcome. We will continue our efforts so that more animals with congenital heart disease can lead healthy and normal lives.'
NEL Animal Cardiovascular Center is preparing an academic analysis and official report on this case, and sincerely hopes that this achievement contributes to the advancement of veterinary cardiac surgery not only in Korea, but also across Asia.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250618427466/en/
CONTACT: NEL Animal Cardiovascular Center
Yoon il-yong
+82-31-421-7579
[email protected]
KEYWORD: ASIA PACIFIC SOUTH KOREA
INDUSTRY KEYWORD: CARDIOLOGY VETERINARY BIOTECHNOLOGY PETS SURGERY HEALTH HEALTH TECHNOLOGY CONSUMER
SOURCE: NEL Animal Cardiovascular Center
Copyright Business Wire 2025.
PUB: 06/22/2025 08:00 PM/DISC: 06/22/2025 07:59 PM
http://www.businesswire.com/news/home/20250618427466/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
9 hours ago
- Newsweek
Three-Legged Dog Gives Up on Fetch—Then Something Amazing Happens
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hearts have melted at the bond between a three-legged dog and her best friend, who helped her find her love of fetch again. Asia the chocolate Labrador retriever is 6 years old, and, earlier this year, lost a leg to cancer, after her dedicated owners spotted a "small lump" in her paw. "Because we caught this so early, it meant we could save her life by amputating the leg as the cancer had not spread to the rest of her body," her owner Jared Power, from East Yorkshire in the U.K., told Newsweek. Now, happily, "the vets have declared her cancer-free," and Asia is slowly but surely getting to grips with life with three legs. Five months after her surgery, Power said that Asia is "regaining her old life back," with the help of hydrotherapy to "strengthen her legs and build stamina." Another big help has been her "best friend," Kiki—a 1-year-old chocolate Labrador who lives just around the corner with her owners Nathan and Nikki, and who became friends with Asia thanks to the power of TikTok. After noticing each other on walks with each of their labs, Nathan and Nikki then spotted Asia on TikTok, and began messaging Power and his partner, Scott Oldridge, to organize a meetup. "They instantly became best friends; in fact, they are like sisters.," Power said. "They look and act so much like each other, and Kiki has really looked after Asia and brought new life into her." This bond was showcased in a video to Asia's account @ on August 15, as the two dogs played fetch together in a park. But as the ball soared across the field, Asia quickly realized she couldn't keep up with Kiki, and simply stood back, watching her run for the ball. But something amazing then happened, as Power described it in the video: "Her best friend could sense Asia was upset, so she stood by and cheered her on." Asia hangs back from fetch, left; and right, Kiki gives her space to chase the ball at her own pace. Asia hangs back from fetch, left; and right, Kiki gives her space to chase the ball at her own pace. TikTok @ This time, as the ball was flung across the field, Kiki didn't move—and Asia rushed toward the ball at her own pace. Kiki moved only once it was time to greet Asia on her return, the ball now successfully in her mouth. "I'm not crying, you are," Power wrote over the video, and added in the caption: "Dogs really are something magical, and we don't deserve them. "Kiki, her best friend, could see her struggling, so something special happened when she decided to cheer Asia on." Power said: "Whenever they are together, they play so gently—I think that Kiki can sense that Asia is a little more fragile. "People think dogs do not have emotions, but my video proves otherwise; you can see so much emotion conveyed in the clip! Kiki really wanted her best friend to feel happy." TikTok users were in tears, watching the video more than 3 million times and awarding it more than 559,000 likes, as one commenter thanked Power: "I needed a happy cry." "Jokes on you, I meant to cry at 8:47 a.m. on a Friday morning," another posted, while a third commented: Yes. I am in fact crying." And as a fourth put it: "I was not emotionally prepared for this." From left: Asia and Kiki rest on the grass; and wear party hats. From left: Asia and Kiki rest on the grass; and wear party hats. TikTok @ Dogs can cope well on three legs, but it can take time to adapt. After amputation, owners should follow the vet's aftercare instructions carefully, and look into a slowly increasing exercise program to build strength in their remaining limbs, pet-food manufacturer Purina says. Ensure the dogs' favorite places, such as the sofa or bed, are easily accessible via ramps or steps, and keep a close eye on their weight, as any gain could put a strain on their remaining limbs. Allow plenty of time for rehabilitation and adjustment, and don't be afraid to seek more information from professionals if you have any concerns. Do you have funny and adorable videos or pictures of your pet you want to share? Send them to life@ with some details about your best friend, and they could appear in our Pet of the Week lineup.
Medscape
11 hours ago
- Medscape
Stapokibart Improves Rhinosinusitis With Nasal Polyps
Addition of the monoclonal antibody stapokibart significantly improved nasal polyps and nasal congestion in adults with uncontrolled chronic rhinosinusitis with nasal polyps, based on new data from 179 individuals. Biologics are now more commonly used as treatments for chronic rhinosinusitis with nasal polyps (CRSwNP), and monoclonal antibodies have emerged as significantly more effective than other biologics for these patients, wrote Shen Shen, MS, of Capital Medical University, Beijing, China, and colleagues. In a study known as CROWNS-2 published in JAMA , the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 mg subcutaneously) or a placebo injection every 2 weeks for 24 weeks. All participants also received 100 μg of mometasone furoate per nostril once a day as background treatment before and during the study. The co-primary endpoints were changes in nasal polyp score and nasal congestion score from baseline to 24 weeks in the study population overall and in the subgroup with eosinophilic chronic rhinosinusitis with nasal polyps. The 24-week double-blind period was followed by an open-label extension to 52 weeks. Key secondary endpoints included the percentage of patients who achieved improvement of 1 point or more on nasal polyp scores and 2 points or more on nasal polyp scores. The final analysis included 90 individuals in the stapokibart group and 89 in the placebo group. The mean age of the study population was 45 years, and approximately one third were women. The mean duration of CRSwNP was 6.0 years, and 139 patients (77.7%) had eosinophilic CRSwNP. Study Outcomes Compared with placebo patients at 24 weeks, patients in the stapokibart group had a significant reduction in polyp size, with least-squares mean (LSM) changes in nasal polyp score from baseline of -2.6 and -0.3 points, respectively ( P < .001). Similarly, patients in the stapokibart group had a significantly greater LSM change in nasal congestion score from baseline to week 24 than those in the placebo group (-1.2 points vs -0.5 points, respectively; P < .001). Nearly all of the patients treated with stapokibart (96.5%) had a reduction in nasal polyp score of at least 1 point, and 89.5% had a reduction of at least 2 points after 52 weeks. The improvements in both primary endpoints were even greater among patients with eosinophilia, with an LSM change of -3.0 vs -0.04 for nasal polyp scores and -1.3 vs -0.5 for nasal congestion scores in stapokibart vs placebo patients, respectively. The overall incidence of adverse events in the first 24 weeks of the study was similar for the stapokibart and placebo groups. The most common adverse events were upper respiratory tract infections, COVID-19, and unconfirmed but suspected COVID-19. Serious adverse events were rare and similar between the stapokibart and placebo groups (2.2% vs 1.1%). However, higher rates of arthralgia and hyperuricemia were reported with stapokibart than with placebo (7.8% vs 0% and 5.6% vs 1.1%, respectively). The findings were limited by several factors, including the lack of data on aspirin-exacerbated respiratory disease, the small numbers of patients, and the inclusion only of patients in China, the researchers noted. However, the results support the potential of stapokibart to reduce nasal polyp size and symptom severity in adults with severe CRSwNP, they concluded. Emergence of Endotyping The significant reduction in polyp score was the study's most notable finding, according to an accompanying editorial. 'The emergence of biologic therapies for chronic rhinosinusitis with nasal polyps has brought the concept of inflammatory endotyping to the forefront of this condition,' wrote Michael P. Platt, MD, of Boston University Chobanian & Avedisian School of Medicine, Boston; Stacey T. Gray, MD, of Harvard Medical School, Boston; and Anju T. Peters, MD, of Northwestern University Feinberg School of Medicine, Chicago. The current study included a majority of individuals with eosinophilic CRSwNP, and the successful reduction in polyp size was based on correct identification of this T2 endotype, as stapokibart targeted T2 inflammation, they said. However, choosing the appropriate biologic therapy for uncontrolled CRSwNP with nasal polyps also requires consideration of other comorbid atopic diseases and disease pathogenesis, with shared decision-making, they added. Tuning in to Eosinophilia 'Currently, three biologics are approved for CRSwNP in the US, with additional agents likely to follow,' said Michael S. Blaiss, MD, an allergist and clinical professor at the Medical College of Georgia at Augusta University, Augusta, Georgia, in an interview. 'What distinguishes this trial is that the investigators specifically defined and studied eosinophilic CRSwNP,' said Blaiss, who was not involved in the study. 'In this subgroup, the biologic demonstrated significant efficacy, providing important data for this population of CRSwNP sufferers,' he said. The study findings were not unexpected, as stapokibart has a similar mechanism of action to dupilumab, said Blaiss. 'Both target the IL-4Rα [interleukin-4 receptor subunit alpha] receptor, albeit at different binding sites and affinities, and dupilumab is already FDA-approved for CRSwNP, so efficacy was expected,' he said. 'However, safety findings warrant attention,' he emphasized. The significantly greater occurrence of arthralgia and hyperuricemia in stapokibart vs placebo patients deserves further evaluation in larger and longer studies, Blaiss said. 'If approved, this biologic would provide an additional treatment option for patients with moderate to severe CRSwNP,' Blaiss told Medscape Medical News . However, its advantages over currently available biologics remain unknown, as the dosing schedule of every 2 weeks does not improve convenience, he noted. 'Head-to-head comparative studies are needed, similar to the recent dupilumab vs omalizumab trial in CRSwNP, to determine whether one biologic is clinically superior,' said Blaiss. 'Furthermore, evaluation in noneosinophilic CRSwNP is necessary, as the present study included too few patients in this subgroup for meaningful statistical analysis,' he added.
Bloomberg
14 hours ago
- Bloomberg
FDA Warns Against Eating Shrimp Brand, Citing Radioactive Matter
The US Food and Drug Administration has advised the public not to eat a brand of shrimp sold at Walmart Inc. over concerns about radioactive contamination. The agency told Walmart to pull three lots of raw frozen shrimp sourced from Indonesia after officials detected radioactive Cesium-137 in a shipment that did not enter the US, the FDA said in a statement on Tuesday. The isotope can lead to an elevated risk of cancer through repeated exposure to low doses, though the detected levels were not high enough to cause an acute risk, the FDA said.
